Grant: Engage Grants Program
University of Guelph
$24,822.00
Phytoglycogen nanoparticles as antibacterial drug delivery agents
FY 2015-16
Summary
PhytospherixTM nanoparticles are a proprietary biomaterial generated by Mirexus Inc. (Guelph, ON) from Ontario-grown sweet corn, and are natural, biodegradable, non-toxic and edible. These desirable properties can be used in a wide range of applications for nutraceuticals, cosmetics and pharmaceuticals, all of which must meet stringent regulatory requirements. The high density of active surface hydroxyl groups results in a unique combination of properties, such as very fast dissolution in water, low viscosity in aqueous solutions up to 25 % and shear thinning effects at higher concentrations. PhytospherixTM can be modified to carry antibiotics. The ability to tune its uniform surface chemistry can be exploited to ensure high efficacy as a carrier. This last feature is especially pertinent because few new antibiotics are anticipated to enter the market. This is a
globally-recognised concern since pathogenic bacteria continue to develop resistance to most commercially available antibiotics. Furthermore, certain pathogenic bacteria can infect and survive as intracellular pathogens within host cells, including those cells of the immune system that are supposed to kill them. Once inside the cell, pathogens are more protected; higher antibiotics doses are needed to kill the internalised bacteria yet such high doses are often undesirable. Strong interest in novel antimicrobials has driven research in nano-enabled delivery systems. Such systems offer numerous benefits - reductions in dosage and systemic toxicity, increased bioavailability, targeted delivery, and controlled release.
Mirexus has the in-house capability to produce high quality samples and to conjugate a wide variety of bioactive materials to PhytospherixTM but lacks the expertise and facilities to assess the antimicrobial properties of the proposed conjugates. The company seeks to address this by establishing a collaborative partnership with scientific expertise in the areas of microbial physiology, bacteria-nanoparticle material interactions and antimicrobials, and access to research facilities. Accessing these capabilities is vital to assess the commercialization potential of PhytospherixTM as a drug delivery agent.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
485333-2015
Name nom
Glasauer, Susan
Department département
Environmental Sciences, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
24822
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Partie
1
Nb partie
1
Application title
Phytoglycogen nanoparticles as antibacterial drug delivery agents
Keyword
NSERC
Application summary
PhytospherixTM nanoparticles are a proprietary biomaterial generated by Mirexus Inc. (Guelph, ON) from Ontario-grown sweet corn, and are natural, biodegradable, non-toxic and edible. These desirable properties can be used in a wide range of applications for nutraceuticals, cosmetics and pharmaceuticals, all of which must meet stringent regulatory requirements. The high density of active surface hydroxyl groups results in a unique combination of properties, such as very fast dissolution in water, low viscosity in aqueous solutions up to 25 % and shear thinning effects at higher concentrations. PhytospherixTM can be modified to carry antibiotics. The ability to tune its uniform surface chemistry can be exploited to ensure high efficacy as a carrier. This last feature is especially pertinent because few new antibiotics are anticipated to enter the market. This is a
globally-recognised concern since pathogenic bacteria continue to develop resistance to most commercially available antibiotics. Furthermore, certain pathogenic bacteria can infect and survive as intracellular pathogens within host cells, including those cells of the immune system that are supposed to kill them. Once inside the cell, pathogens are more protected; higher antibiotics doses are needed to kill the internalised bacteria yet such high doses are often undesirable. Strong interest in novel antimicrobials has driven research in nano-enabled delivery systems. Such systems offer numerous benefits - reductions in dosage and systemic toxicity, increased bioavailability, targeted delivery, and controlled release.
Mirexus has the in-house capability to produce high quality samples and to conjugate a wide variety of bioactive materials to PhytospherixTM but lacks the expertise and facilities to assess the antimicrobial properties of the proposed conjugates. The company seeks to address this by establishing a collaborative partnership with scientific expertise in the areas of microbial physiology, bacteria-nanoparticle material interactions and antimicrobials, and access to research facilities. Accessing these capabilities is vital to assess the commercialization potential of PhytospherixTM as a drug delivery agent.